Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers

Sponsor
Bristol-Myers Squibb
Study ID
NCT07791199
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
4 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have completed their qualified parent studies and/or long-term extension if applicable.

Key Dates

First listed
Aug 27, 2026
Start date
Sep 2, 2026
Status verified
Aug 2026
Primary completion
Oct 31, 2030
Completion
Oct 31, 2030

Study Design

Enrollment
2,300 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Deucravacitinib Arm

Primary Outcome Measure

Number of participants treated [ Time Frame: Up to approximately 28 days after last dose of deucravacitinib ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Find similar trials

Nationwide
Psoriasis trialsPsoriatic arthritis trialsLupus (SLE) trialsDermatology trialsRheumatology trialsAutoimmune disease trialsMusculoskeletal disorders trials

Related Studies